AMSTERDAM (MedPage Today) — The investigational oral drug teriflunomide (Aubagio) seems to have maintained its effectiveness during up to nine years of follow-up in clinical trial patients with the relapsing form of multiple sclerosis, and no late safety problems have been noticed, researchers said here.
http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/29299
Sent with MobileRSS for iPhone
Júlio Leonardo B. Pereira
http://lattes.cnpq.br/7687651239699170
http://www.neurocirurgiabr.orghttp://www.neurocancer.com
